Modified GRF (1-29)

Modified GRF (1-29), also known as Mod GRF 1-29, is a synthetic peptide that is used in the field of pharmacology and biochemistry. It is a modified version of the shortest fully functional fragment of the Growth Hormone-Releasing Hormone (GHRH), which is responsible for the growth hormone release in the human body.

History

Modified GRF (1-29) was developed after the discovery of the naturally occurring hormone, GHRH. Scientists modified the structure of GHRH to create a synthetic peptide with improved stability and efficacy. The number 1-29 refers to the position of the amino acids in the peptide chain that are responsible for its biological activity.

Structure and Function

Modified GRF (1-29) is a 29 amino acid peptide, which is the same length as the active portion of GHRH. It has been modified to increase its stability and potency. The modifications include the substitution of the 2nd, 8th, 15th and 27th amino acids, and the addition of a terminal amide group.

The primary function of Modified GRF (1-29) is to stimulate the release of growth hormone from the pituitary gland. It does this by binding to the GHRH receptor on the pituitary cells, triggering a cascade of events that leads to the release of growth hormone.

Pharmacology

In pharmacological studies, Modified GRF (1-29) has been shown to have a potent effect on growth hormone release. It has a half-life of about 30 minutes, which is significantly longer than that of natural GHRH. This makes it a useful tool in research and potentially in the treatment of conditions related to growth hormone deficiency.

Potential Applications

While Modified GRF (1-29) is primarily used in research, it has potential applications in the treatment of conditions such as growth hormone deficiency, muscle wasting diseases, and certain forms of dwarfism. However, more research is needed to fully understand its effects and potential side effects.

See Also

• Growth Hormone-Releasing Hormone
• Growth hormone
• Pituitary gland
• Peptide

‎

‎